The Pulse
Hims just posted its best month since March, and it is buying the whole funnel.
Hims stock climbed about 36% in June, and Barclays lifted its price target to $39 from $29 on the back of the weight-loss business.
Under that run is a strategy worth watching: a Novo Nordisk GLP-1 partnership, the completed Eucalyptus acquisition, a new chief medical officer, and a teased Oura wearable integration.
The incumbent is verticalizing supply, platform, and patient data at once. If you run a smaller brand, the lesson is not to copy the spend. It is to defend the one thing they cannot buy from you, which is the patient relationship.
Employers are dropping GLP-1 coverage, and that lands on telehealth.
Analysts expect Hims and rivals to gain as employers cut weight-loss drug coverage to control costs, pushing patients toward cash-pay.
A wave of cash-pay patients sounds like a gift. But a patient who lost insurance coverage is price-led by definition, and price-led patients churn first when a cheaper option appears.
Treat the coverage cliff as an acquisition tailwind and a retention trap at the same time. The brands that win these patients lead with outcomes, not the lowest monthly price.
The compounding door is closing, and the comment window shuts June 29.
The FDA's proposal to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulk list is in its final public comment period, closing June 29.
If it finalizes, the cheap compounded scripts a lot of patients are on go away, and those patients face a price step or a switch to branded or oral.
That makes your compounded-script cohort the highest flight risk of the summer. You want to know exactly who they are before the change hits, not after they cancel.
The Deep Dive
The patient walking into your funnel in the second half of 2026 is not the patient your onboarding flow was built for.
For three years, the typical GLP-1 starter was high-intent. They fought through cost, hesitation, and a needle to get on treatment. That effort did a lot of your retention work for you.
That patient is now becoming the minority of your intake.
From July 1, eligible Medicare patients can get an oral GLP-1 for around $50 a month. Employers dropping coverage are pushing others into cash-pay. Prices keep sliding, and a daily pill removed the needle.
Access got easier. So the new patient is, on average, less committed, more price-curious, and faster to quit.
A single onboarding flow now serves two very different patients.
Most brands run one onboarding sequence for everyone who starts.
That worked when everyone arrived with similar intent. It breaks when half your intake is a $50 pill starter testing the waters and the other half is a $300 cash-pay injectable patient who chose you deliberately.
Send them the same day-1 email and you over-serve one and lose the other.
Commitment leaves a signal at signup. Use it.
You already capture the data that predicts month-1 churn. You are just not branching on it.
Entry price or plan length. A monthly $50 start is a weaker commitment than a prepaid quarter.
Format. Oral pill starters quit more quietly than injectable patients, because a daily pill blends into the background.
Source. An insurance-cliff cash-pay patient behaves differently from one who came through your content.
Branch the onboarding flow on those signals and the low-commitment cohort gets what it actually needs.
The new cohort needs more reassurance, sooner.
The KB lifecycle map is clear on where these patients break.
Day 0 to 14 is expectation setting, when the anxious starter decides if this was a mistake. Day 15 to 28 is the side-effect window, when GI discomfort tempts a quiet pause.
The committed patient rides through both. The low-commitment starter needs a heavier early touch: front-loaded education, a day-3 "this is normal" check-in, and a clear reason to stay that is about results, not the price they paid.
The takeaway. Acquisition is about to get easier for everyone, which means onboarding is where the next year of retention is won or lost. Split your onboarding flow by commitment signal before the July wave lands, so the patient who barely committed gets the reassurance that keeps them, and the patient who chose you on purpose is not buried in remedial emails.
Quick Takes
You do not need a wearable deal to act on patient signals.
Hims teasing an Oura integration makes continuous data look like an incumbent-only game. It is not.
You already hold the signals that predict churn: a skipped refill, a gone-quiet portal, an unanswered check-in. Most brands collect them and trigger on none of them. Wire one of those into a save touch and you get the retention value without the wearable budget.
When the incumbent owns the supply chain, the relationship is what is left to compete on.
Hims now touches the molecule, the platform, and soon the wearable. You will not out-integrate that.
What does not come with their scale is a patient who feels personally guided through month one. That is the asset you can still build better than they can, and it is the one that keeps patients when a cheaper option shows up.
One Thing to Try
Pull your last 90 days of new patients and split them into two groups by entry commitment: lowest-price or monthly starts in one, prepaid or multi-month starts in the other.
Compare the month-1 cancellation rate between the two.
If the low-commitment group churns faster, and it almost always does, you have just found the cohort your single onboarding flow is failing.
Build one extra early touch for that group this week: a day-3 provider-voice check-in that sets expectations and names the most common first-two-weeks’ concern for your treatment.
Takes an afternoon to set up. It is the cheapest place to catch the July wave before it leaks.
If retention is your biggest revenue leak, that’s what we fix. growthtrigger.xyz
Reply to this with your biggest retention challenge. I read and respond to every single one.